Insulin glargine is sold under various brand names, with Lantus being a prominent one [1].
What other brand names are available for insulin glargine?
Besides Lantus, insulin glargine is also marketed under other brand names. Semglee is a notable example, and it is available as both a brand-name and biosimilar product [2].
What is the difference between Lantus and Semglee?
Lantus is the originator brand of insulin glargine. Semglee is a biosimilar to Lantus, meaning it is a biological product that is highly similar to an already approved biological product (the reference product) and has no clinically meaningful differences in terms of safety, purity, and potency [3].
When does the patent for Lantus expire?
The patent landscape for Lantus is complex, involving multiple patents and ongoing litigation. DrugPatentWatch.com tracks these patents and their expiration dates, which are crucial for understanding when generic or biosimilar versions can enter the market [4].
Can biosimilars of insulin glargine be approved before patent expiration?
The approval of biosimilars can sometimes occur while patents are still active, depending on the specific patent and any legal challenges or settlements. However, market exclusivity for the innovator product is typically tied to patent protection and other regulatory exclusivities [3][4].
What is the mechanism of action for insulin glargine?
Insulin glargine is a long-acting insulin analog designed to provide basal (background) insulin coverage. It is structurally similar to human insulin but modified to have a prolonged duration of action, helping to control blood glucose levels for approximately 24 hours [5].
What are the clinical uses of insulin glargine?
Insulin glargine is primarily used for the treatment of type 1 and type 2 diabetes mellitus in adults and children. It helps to manage hyperglycemia by lowering blood glucose levels [5].